Amicus Therapeutics, Inc. (FOLD) Short Interest Down 23.0% in January

Amicus Therapeutics, Inc. (NASDAQ:FOLD) was the recipient of a large decrease in short interest in January. As of January 31st, there was short interest totalling 22,063,910 shares, a decrease of 23.0% from the January 15th total of 28,648,935 shares. Currently, 12.0% of the company’s shares are sold short. Based on an average daily volume of 2,934,535 shares, the days-to-cover ratio is currently 7.5 days.

In other Amicus Therapeutics news, COO Bradley L. Campbell sold 36,000 shares of the stock in a transaction that occurred on Tuesday, January 22nd. The shares were sold at an average price of $11.81, for a total value of $425,160.00. Following the completion of the sale, the chief operating officer now owns 275,360 shares of the company’s stock, valued at $3,252,001.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO John F. Crowley sold 20,000 shares of the stock in a transaction that occurred on Friday, February 1st. The shares were sold at an average price of $12.12, for a total transaction of $242,400.00. Following the completion of the sale, the chief executive officer now directly owns 688,081 shares of the company’s stock, valued at approximately $8,339,541.72. The disclosure for this sale can be found here. In the last three months, insiders have sold 212,769 shares of company stock valued at $2,520,371. Corporate insiders own 2.90% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the company. Marshall Wace LLP purchased a new position in shares of Amicus Therapeutics during the 3rd quarter valued at approximately $14,096,000. AXA boosted its stake in shares of Amicus Therapeutics by 113.1% during the 3rd quarter. AXA now owns 1,218,691 shares of the biopharmaceutical company’s stock valued at $14,734,000 after buying an additional 646,739 shares during the last quarter. First Trust Advisors LP boosted its stake in shares of Amicus Therapeutics by 15.8% during the 3rd quarter. First Trust Advisors LP now owns 213,396 shares of the biopharmaceutical company’s stock valued at $2,580,000 after buying an additional 29,046 shares during the last quarter. Man Group plc boosted its stake in shares of Amicus Therapeutics by 469.2% during the 3rd quarter. Man Group plc now owns 218,786 shares of the biopharmaceutical company’s stock valued at $2,645,000 after buying an additional 180,351 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its stake in shares of Amicus Therapeutics by 7.7% during the 3rd quarter. Janus Henderson Group PLC now owns 8,806,359 shares of the biopharmaceutical company’s stock valued at $106,469,000 after buying an additional 627,972 shares during the last quarter.

Shares of NASDAQ:FOLD opened at $10.97 on Tuesday. The company has a debt-to-equity ratio of 0.78, a current ratio of 9.12 and a quick ratio of 9.03. Amicus Therapeutics has a 52-week low of $8.27 and a 52-week high of $17.62. The company has a market capitalization of $2.12 billion, a price-to-earnings ratio of -3.76 and a beta of 1.77.

Several analysts have issued reports on the stock. Zacks Investment Research raised shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, February 4th. ValuEngine downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, February 5th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Amicus Therapeutics in a research report on Tuesday, February 5th. Guggenheim assumed coverage on shares of Amicus Therapeutics in a research report on Monday, December 17th. They issued a “buy” rating and a $18.00 price objective for the company. Finally, Citigroup assumed coverage on shares of Amicus Therapeutics in a research report on Monday, October 29th. They issued a “neutral” rating and a $12.00 price objective for the company. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the stock. Amicus Therapeutics has an average rating of “Hold” and a consensus target price of $18.60.

COPYRIGHT VIOLATION WARNING: “Amicus Therapeutics, Inc. (FOLD) Short Interest Down 23.0% in January” was originally reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2019/02/12/amicus-therapeutics-inc-fold-short-interest-down-23-0-in-january.html.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.

Featured Article: How to use beta for portfolio diversification

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply